Sponsor: Amgen Inc.

This study will investigate longitudinal changes in brain structure and function in high frequency episodic and chronic migraine patients who are responding to erenumab treatment compared to those patients who are non-responders. In addition, pre-treatment and early post-treatment brain imaging data will be used to build models that predict which individual migraine patients will respond to erenumab treatment.